Literature DB >> 23032144

Does cigarette smoking exacerbate the effect of blood pressure on the risk of cardiovascular and all-cause mortality among hypertensive patients?

Zeng Ge1, Yongchen Hao, Jie Cao, Jianxin Li, Jichun Chen, Jianfeng Huang, Xigui Wu, Dongfeng Gu.   

Abstract

OBJECTIVE: To examine the risk of cigarette smoking on cardiovascular disease (CVD) and all-cause mortality among hypertensive patients.
METHODS: We conducted a prospective cohort study among 36,943 hypertensive patients aged at least 40 years. Data on smoking and other variables were obtained in 1991 and follow-up evaluation was conducted in 1999-2000.
RESULTS: During a median follow-up of 8.2 years, we documented 7194 deaths among 36 943 hypertensive patients. Compared with never-smokers, the multivariate-adjusted relative risks (MRRs) [95% confidence intervals (CIs)] for CVD mortality were 1.19 (1.07, 1.31) and 1.33 (1.23, 1.45) for those who smoked 0.1-19 pack-years and at least 20 pack-years (P for linear trends <0.001 for all). A similar pattern was observed for all-cause mortality. A dose-response association between pack-years smoked and risk of CVD and all-cause mortality (all P ≤ 0.01) was found among the SBP groups (140-159, 160-179, and ≥ 180 mmHg), DBP groups (<90, 90-94, and 100-109 mmHg), and pulse pressure groups (50-59, 60-69, and ≥ 70 mmHg). In addition, compared to never-smokers with stage 1 hypertension, MRRs of CVD and all-cause mortality for those who smoked at least 20 pack-years with stage 3 hypertension were remarkably increased to 3.06 (2.64, 3.54) and 2.51 (2.24, 2.80), respectively.
CONCLUSIONS: Smoking not only significantly increased the risk of CVD and all-cause mortality among hypertensive groups, but the synergistic effect on the risk of CVD and all-cause mortality existed between cigarette smoking and blood pressure category. Therefore, apart from hypertension management, smoking cessation should be an essential component for preventing deaths related to smoking.

Entities:  

Mesh:

Year:  2012        PMID: 23032144     DOI: 10.1097/HJH.0b013e328359aa1f

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Predictive Performance of Pender's Health Promotion Model for Hypertension Control in Iranian Patients.

Authors:  Fatemeh Gorbani; Hassan Mahmoodi; Parvin Sarbakhsh; Abdolreza Shaghaghi
Journal:  Vasc Health Risk Manag       Date:  2020-07-17

2.  Cigarette smoking exacerbates the adverse effects of age and metabolic syndrome on subclinical atherosclerosis: the Bogalusa Heart Study.

Authors:  Shengxu Li; Miaoying Yun; Camilo Fernandez; Jihua Xu; Sathanur R Srinivasan; Wei Chen; Gerald S Berenson
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

3.  Smoking, Blood Pressure, and Cardiovascular Disease Mortality in a Large Cohort of Chinese Men with 15 Years Follow-up.

Authors:  Jibin Tan; Xiumin Zhang; Weihua Wang; Peng Yin; Xiaomin Guo; Maigeng Zhou
Journal:  Int J Environ Res Public Health       Date:  2018-05-18       Impact factor: 3.390

4.  Joint association of smoking and physical activity with mortality in elderly hypertensive patients: A Chinese population-based cohort study in 2007-2018.

Authors:  Yating Yang; Huilin Xu; Xiaoqin Liu; Jiong Li; Zeyan Liew; Xing Liu; Chen Huang; Jingjing Zhu; Jinling Zhang; Linli Chen; Yuantao Hao; Guoyou Qin; Yongfu Yu
Journal:  Front Public Health       Date:  2022-09-29

5.  Synergistic and Non-synergistic Associations for Cigarette Smoking and Non-tobacco Risk Factors for Cardiovascular Disease Incidence in the Atherosclerosis Risk In Communities (ARIC) Study.

Authors:  Jay H Lubin; David Couper; Pamela L Lutsey; Hiroshi Yatsuya
Journal:  Nicotine Tob Res       Date:  2017-07-01       Impact factor: 4.244

6.  Lifestyle factors, medication use and risk for ischaemic heart disease hospitalisation: a longitudinal population-based study.

Authors:  Anthony S Gunnell; Kristjana Einarsdóttir; Daniel A Galvão; Sarah Joyce; Stephania Tomlin; Vicki Graham; Caroline McIntyre; Robert U Newton; Tom Briffa
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.